?
Therapeutic Target**: Is MYO10 the best therapeutic target, or should downstream effectors be considered?
active
open question
Created: 2026-04-25T20:28:40
By: backfill_open_questions
Quality:
50%
✓ SciDEX
ID: open_question-0b373a84-3be2-4b67-8efd-38
Open Question
open
Wiki: mechanisms-myo10-mitochondrial-transfer
Therapeutic Target**: Is MYO10 the best therapeutic target, or should downstream effectors be considered?
Importance Elo
1500
Field Rank
Rank #1089 in mechanisms
Tractability
0.50
Potential Impact
0.50
Evidence Summary
Extracted from wiki page mechanisms-myo10-mitochondrial-transfer
Secondary Market
No secondary market activity yet. Learn about share issuance →
Share Holder Leaderboard
No shares issued yet.
Evidence Bearing On This Question
No cross-references found yet. Evidence matching runs daily.
Pairwise Tournament History
No pairwise judgments recorded yet.
Derived Hypotheses And Proposals
No derived artifacts linked yet.
Related Entities
▸Metadata
| status | open |
| _origin | {'url': None, 'type': 'internal', 'tracked_at': '2026-04-26T03:28:40.386165'} |
| field_tag | mechanisms |
| source_id | mechanisms-myo10-mitochondrial-transfer |
| sub_field | myo10-mitochondrial-transfer |
| source_kind | wiki |
| question_hash | 6632b6be4f0e1146300d472a0e4f07c5c444335a3db92e5492afedb4851cd960 |
| question_text | Therapeutic Target**: Is MYO10 the best therapeutic target, or should downstream effectors be considered? |
| importance_elo | 1500 |
| _schema_version | 1 |
| evidence_summary | Extracted from wiki page mechanisms-myo10-mitochondrial-transfer |
| tractability_score | 0.5 |
| potential_impact_score | 0.5 |
📊 Evidence Profile
Evidence Balance
+0%
Certainty
0%
Debates
0
Incoming
0
Outgoing
1
0 supporting
0 contradicting
0 neutral
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.